WallStreet Research Initiates Profile Coverage of Pressure BioSciences, Inc.

SOUTH EASTON, Mass., July 8, 2009 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" or "the Company") today announced that WallStreet Research(tm) ("WSR"), a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company LLC ("ASC"), has commenced profile coverage of the Company. The corporate profile, together with additional information about WallStreet Research, is available at the www.WallStreetResearch.org website.

Mr. Richard T. Schumacher, President & CEO of Pressure BioSciences, stated: "We are pleased to have established a relationship with WallStreet Research, resulting in the publishing of our corporate profile on their website. We have also accepted an invitation to discuss our many recent accomplishments, including the early release of our much anticipated PCT MicroTube Adapter Kit on June 1st, to a select group of investment bankers, portfolio managers, institutional and other accredited investors at the Fifth Annual WSR Small Cap Conference (www.SmallCapConference.org), to be held in New York City on August 11th-12th at the Penn Club."

Mr. Alan Stone, Managing Director of WallStreet Research, added: "WSR is very impressed with Pressure BioSciences' management, focused business strategy, and cutting-edge PCT technology. We strongly believe that their current base of well-known customers, the increasing market acceptance of PCT, their strong intellectual property estate, and the large and growing sample preparation market into which they sell their products, form a solid foundation to help ensure PBI's growth and success."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

About WallStreet Research(tm)

WallStreet Research(tm) (WSR) is a prominent research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and smallcap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Insurance Company's Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida.

Forward-Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Disclaimer

The information presented in the WSR report is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities referred to therein or otherwise. Readers are encouraged to conduct their own due diligence and review all of the company's financial statements and risks statements on file with the SEC. Pressure BioSciences, Inc. has paid a consulting fee of $6,000 to ASC in conjunction with the preparation and distribution of the corporate profile and participation in the WSR conference. ASC or its associates may own shares, for investment purposes, in its corporate accounts, and may increase or decrease its positions at any time, without notice.

CONTACT:  Pressure BioSciences, Inc.
          Richard T. Schumacher, President & CEO
            rschumacher@pressurebiosciences.com
          R. Wayne Fritzsche, Chairman
            wfritzsche@pressurebiosciences.com
          (508) 230-1828
          www.pressurebiosciences.com

          WallStreet Research(tm)
          Alan Stone, Managing Director
          (212) 521-4102
          astone@alanstone.com
          www.WallStreetResearch.org
          www.SmallCapConference.org

Released July 8, 2009